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Background: Co-existent MR increases both early and late mortality following SAVR. Whether preoperative MR affects clinical outcomes of patients 
undergoing TAVR is controversial.
methods: Data were drawn from the randomized PARTNER Trial of patients with severe aortic stenosis undergoing either TAVR (167 patients from 
cohort B [inoperable] and 329 from cohort A [operable high-risk]) or SAVR (n=297 from cohort A). Both TAVR and SAVR patients were dichotomized 
according to the degree of preoperative MR (moderate/severe vs. none/mild) on core lab-adjudicated echocardiography.
results: At baseline, moderate or severe MR was reported in 37 TAVR-B (22.1%), 65 TAVR-A (19.7%), and 63 SAVR-A patients (21.2%). Thirty-day 
changes in MR degree suggest a greater improvement in mod MR with SAVR vs. TAVR (table 1). At 2-year follow-up, SAVR patients with moderate or 
severe MR had a higher mortality than those with ≤mild MR (49.8% vs 28.1%; adjusted hazard ratio (HR): 1.73; 95% confidence interval (CI)[1.01-
2.96], p=0.04). In contrast, the degree of MR at baseline did not affect mortality in TAVR patients (39.1% vs 36.1%, moderate/severe vs none/mild; 
HR: 1.05; [0.72-1.54], p=0.81).
conclusions: Although SAVR results in a significant immediate improvement in baseline mitral regurgitation compared to TAVR, moderate or 
severe MR at baseline is associated with higher 2-year mortality after SAVR. The presence of moderate or severe MR does not preclude a favourable 
outcome following TAVR.
Table 1
SAVR-cohort
A
TAVR-cohort
A&B
P
value
≤Mild MR
worsened
5 (8.1%) 13 (10.2%) 0.634
Moderate MR
Improved
Unchanged
Worsened
29 (76.3%)
7 (18.4%)
2 (5.3%)
31 (45.6%)
32 (47.1%)
5 (7.35%)
0.008
Severe MR
Improved
Unchanged
Worsened
3 (100%)
0
-
13 (86.7%)
2 (13.3%)
-
0.515
